Intuitive Surgical has shed nearly 8% over the past week, pulling back to $402.30, the lowest print in months — yet options traders have quietly moved to their most call-heavy stance in a year.
The setup is a clean divergence between price action and options positioning. The put/call ratio has fallen to 0.78, the lowest reading of the past 52 weeks — well below its 20-day average of 0.83 and roughly 1.4 standard deviations below the mean. At prior extremes, the PCR peaked above 1.22; it has never been this skewed toward calls in the past year. That signals call demand is unusually high relative to protection-buying, even as the stock itself has dropped 12% over the past month. Separately, the stock's next earnings event is confirmed for July 21, which gives options positioning a specific catalyst to trade around.
Short interest is building but the lending market offers no supporting narrative for bears. SI has climbed 14% over the past week to 2.1% of free float — a meaningful week-on-week jump — though the absolute level remains modest by any standard. Borrowing costs are near the floor at 0.37%, having fallen almost 30% over the past month. Borrow availability is extraordinarily loose — the ratio of available shares to already-borrowed shares is above 9,600%, meaning there is effectively no constraint on new short-sellers entering the trade. The combination of rising short interest and abundant borrow suggests this is incremental bearish conviction, not a positioning squeeze.
The Street remains broadly constructive but has spent the past six weeks resetting price targets lower. BofA Securities — the most recent major action, from May 18 — cut its target sharply from $650 to $520 while holding a Buy rating. The broader cluster of post-earnings target revisions in late April, which came after Q1 results, was dominated by cuts: Barclays trimmed to $651, Piper Sandler to $580, Leerink Partners to $573, Truist to $580. Only Baird bucked the trend, raising its target to $610. The consensus price target now stands at around $565, implying roughly 40% upside from current levels. That gap is large, but its primary cause is that targets were set at a higher price and have not caught down to the stock's correction. The bull case centres on Intuitive's dominance in robotic surgery, strong procedure volume growth, and durable operating leverage from a 10,000-plus da Vinci install base. Bears flag valuation compression risk and management's historically conservative guidance. The EV/EBITDA multiple has compressed roughly 1x over the past month to 24.9x, and the P/E has declined nearly 5 points to 36.6x — both moving in the direction of valuation relief rather than multiple expansion.
Among correlated peers, the week's selloff was broad but not uniform. BSX fell 17% on the week — far more than ISRG's 7.9% — while GMED dropped 8% in line with ISRG. ALGN was the outlier, up nearly 2%. The sector pressure is real, but ISRG's relative decline sits in the middle of the peer pack.
The ORTEX short score has drifted higher over the past two weeks, reaching 33.4 — still in the lower third of its range, consistent with a stock that carries limited short-side urgency. Factor scores reflect the mixed picture: EPS momentum over 90 days ranks in the 70th percentile, earnings surprise history is solid at the 69th, but the forward EPS growth trajectory for the coming year ranks at just the 33rd percentile. Value is not the reason to own this name.
With the July 21 earnings date now on the calendar, the next few weeks reduce to a simple question: whether the call-heavy options positioning and a 40%-premium mean analyst target can coexist with a stock that has broken down 12% in a month, or whether one of those signals has to capitulate first.
See the live data behind this article on ORTEX.
Open ISRG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
